Syngene International Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Syngene International wird ein jährliches Gewinn- und Umsatzwachstum von 14.4% bzw. 13.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.3% betragen.

Wichtige Informationen

17.4%

Wachstumsrate der Gewinne

16.5%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	20.8%
Wachstumsrate der Einnahmen	14.3%
Zukünftige Eigenkapitalrendite	13.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	30 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Jul 16

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10

Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Feb 02

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Nov 26

Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly

Sep 21

Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock

Aug 06

Gewinn- und Umsatzwachstumsprognosen

NSEI:SYNGENE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	51,176	7,889	4,248	N/A	6
3/31/2026	44,722	6,871	3,807	N/A	8
3/31/2025	38,228	5,642	2,806	N/A	8
6/30/2024	34,702	4,923	N/A	N/A	N/A
3/31/2024	34,886	5,100	5,313	10,421	N/A
12/31/2023	35,661	5,002	N/A	N/A	N/A
9/30/2023	34,985	4,984	4,706	10,290	N/A
6/30/2023	33,565	4,839	N/A	N/A	N/A
3/31/2023	31,929	4,644	3,052	8,235	N/A
12/31/2022	29,566	4,334	N/A	N/A	N/A
9/30/2022	28,121	4,277	1,083	5,898	N/A
6/30/2022	26,542	3,924	N/A	N/A	N/A
3/31/2022	26,042	3,958	1,051	5,806	N/A
12/31/2021	25,047	4,086	N/A	N/A	N/A
9/30/2021	24,478	4,068	2,102	6,566	N/A
6/30/2021	23,572	4,242	N/A	N/A	N/A
3/31/2021	21,843	4,049	2,547	7,012	N/A
12/31/2020	21,330	3,645	N/A	N/A	N/A
9/30/2020	20,676	3,541	1,217	6,318	N/A
6/30/2020	20,126	3,981	N/A	N/A	N/A
3/31/2020	20,119	4,121	340	6,771	N/A
12/31/2019	19,385	3,920	N/A	N/A	N/A
9/30/2019	18,865	3,872	1,257	7,549	N/A
6/30/2019	18,405	3,374	N/A	N/A	N/A
3/31/2019	18,256	3,316	471	6,304	N/A
12/31/2018	17,008	3,160	N/A	N/A	N/A
9/30/2018	16,214	3,110	N/A	N/A	N/A
6/30/2018	15,380	3,096	N/A	N/A	N/A
3/31/2018	14,231	3,054	N/A	4,462	N/A
12/31/2017	13,053	2,993	N/A	N/A	N/A
9/30/2017	12,497	2,917	N/A	N/A	N/A
6/30/2017	12,175	2,895	N/A	N/A	N/A
3/31/2017	12,009	2,873	N/A	3,977	N/A
12/31/2016	12,411	2,682	N/A	N/A	N/A
9/30/2016	11,894	2,606	N/A	N/A	N/A
6/30/2016	11,479	2,344	N/A	N/A	N/A
3/31/2016	11,070	2,408	N/A	3,081	N/A
12/31/2015	10,235	2,103	N/A	N/A	N/A
9/30/2015	9,713	1,964	N/A	N/A	N/A
6/30/2015	9,017	1,843	N/A	N/A	N/A
3/31/2015	8,599	1,750	N/A	185	N/A
3/31/2014	6,995	1,339	N/A	2,995	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SYNGENEDas prognostizierte Gewinnwachstum (14.4% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: SYNGENEDie Erträge des Unternehmens (17.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: SYNGENEDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: SYNGENEDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: SYNGENEDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SYNGENEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.3 %).

Syngene International Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.9% to ₹808

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Syngene International Limited Provides Earnings Guidance for the Year 2022

Recent updates

Insider recently sold ₹6.0m worth of stock

MD, CEO & Executive Director recently sold ₹115m worth of stock

Head of Formulations Development recently sold ₹9.6m worth of stock

Syngene International Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited Approves for the Financial Year Ended March 31, 2024

Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024

Syngene International Limited to Report Q1, 2025 Results on Jul 24, 2024

New minor risk - Insider selling

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹4.9m worth of stock

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Head of IT recently sold ₹1.5m worth of stock

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Chief Human Resources Officer recently sold ₹13m worth of stock

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q3, 2023 Results on Jan 23, 2023